Lymphoseek shows promise in sentinel lymph node detection

September 23, 2013

Use of 99mTc-tilmanocept (Lymphoseek, Navidea Biopharmaceuticals) as a SPECT/CT agent can improve preoperative sentinel lymph node localization before surgical treatment for oral cavity squamous cell carcinoma (OSCC), according to a study published in the September issue of JAMA Otolaryngology – Head & Neck Surgery .

The findings suggest 99mTc-tilmanocept could be superior to elective neck dissection (END) or sentinel lymph node biopsy with current agents like sulfur colloid, the former being associated with considerable potential morbidity and the latter having false-negative rates up to 10 percent, according to Anna M. Marcinow, MD, and colleagues at The Ohio State University in Columbus.